JP2002540127A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002540127A5 JP2002540127A5 JP2000607588A JP2000607588A JP2002540127A5 JP 2002540127 A5 JP2002540127 A5 JP 2002540127A5 JP 2000607588 A JP2000607588 A JP 2000607588A JP 2000607588 A JP2000607588 A JP 2000607588A JP 2002540127 A5 JP2002540127 A5 JP 2002540127A5
- Authority
- JP
- Japan
- Prior art keywords
- cholesterol
- level
- lipg
- apolipoprotein
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- 102100031375 Endothelial lipase Human genes 0.000 description 25
- 101000941275 Homo sapiens Endothelial lipase Proteins 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 108010010234 HDL Lipoproteins Proteins 0.000 description 15
- 102000015779 HDL Lipoproteins Human genes 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 15
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 14
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 14
- 238000006911 enzymatic reaction Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000008214 LDL Cholesterol Methods 0.000 description 8
- 108010069201 VLDL Cholesterol Proteins 0.000 description 8
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/277,401 US7008776B1 (en) | 1996-12-06 | 1999-03-26 | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
| US09/277,401 | 1999-03-26 | ||
| PCT/US2000/007870 WO2000057837A2 (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of cholesterol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002540127A JP2002540127A (ja) | 2002-11-26 |
| JP2002540127A5 true JP2002540127A5 (https=) | 2008-06-26 |
Family
ID=23060703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000607588A Pending JP2002540127A (ja) | 1999-03-26 | 2000-03-24 | コレステロールのレベルをもたらすための組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1171078A4 (https=) |
| JP (1) | JP2002540127A (https=) |
| KR (2) | KR20050044812A (https=) |
| AU (1) | AU776684B2 (https=) |
| BR (1) | BR0009333A (https=) |
| CA (1) | CA2363486C (https=) |
| HK (1) | HK1043309A1 (https=) |
| IL (2) | IL145526A0 (https=) |
| MX (1) | MXPA01009727A (https=) |
| NO (2) | NO331779B1 (https=) |
| NZ (2) | NZ531180A (https=) |
| WO (1) | WO2000057837A2 (https=) |
| ZA (1) | ZA200107598B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
| JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物 |
| US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| ES2629630T3 (es) | 2008-12-04 | 2017-08-11 | Curna, Inc. | Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO |
| ES2762610T3 (es) | 2009-02-12 | 2020-05-25 | Curna Inc | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF |
| CN102482677B (zh) | 2009-03-16 | 2017-10-17 | 库尔纳公司 | 通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病 |
| WO2010107740A2 (en) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| ES2609655T3 (es) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP |
| CN103223177B (zh) | 2009-05-06 | 2016-08-10 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
| DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
| CA2762987A1 (en) | 2009-05-22 | 2010-11-25 | Joseph Collard | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
| WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
| US8951981B2 (en) | 2009-06-16 | 2015-02-10 | Curna, Inc. | Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 |
| WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| EP2446037B1 (en) | 2009-06-26 | 2016-04-20 | CuRNA, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
| CN102712925B (zh) | 2009-07-24 | 2017-10-27 | 库尔纳公司 | 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病 |
| CN104313027B (zh) | 2009-08-11 | 2018-11-20 | 库尔纳公司 | 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病 |
| KR101805213B1 (ko) | 2009-08-21 | 2017-12-06 | 큐알엔에이, 인크. | Ｃｈｉｐ에 대한 천연 안티센스 전사체의 억제에 의한 “ｈｓｐ70-상호작용 단백질(ｃｈｉｐ)의 ｃ-말단” 관련된 질환의 치료 |
| CA2771172C (en) | 2009-08-25 | 2021-11-30 | Opko Curna, Llc | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
| US20120295952A1 (en) | 2009-09-25 | 2012-11-22 | Curna, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
| JP6025567B2 (ja) | 2009-12-16 | 2016-11-16 | カッパーアールエヌエー，インコーポレイテッド | 膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療 |
| CN102869776B (zh) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病 |
| RU2619185C2 (ru) | 2009-12-23 | 2017-05-12 | Курна, Инк. | Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2 |
| ES2585829T3 (es) | 2009-12-29 | 2016-10-10 | Curna, Inc. | Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63 |
| EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| CA2785727C (en) | 2009-12-31 | 2020-01-07 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
| CA2785832A1 (en) | 2010-01-04 | 2011-07-07 | Curna, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
| JP6027893B2 (ja) | 2010-01-11 | 2016-11-16 | カッパーアールエヌエー，インコーポレイテッド | 性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療 |
| EP2529015B1 (en) | 2010-01-25 | 2017-11-15 | CuRNA, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
| CN102844435B (zh) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病 |
| RU2612884C2 (ru) | 2010-04-02 | 2017-03-13 | Курна, Инк. | Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3 |
| WO2011127337A2 (en) | 2010-04-09 | 2011-10-13 | Opko Curna Llc | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
| WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病 |
| ES2664585T3 (es) | 2010-05-26 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con metionina sulfóxido reductasa (MSRA) mediante inhibición del transcrito antisentido natural a MSRA |
| US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
| CN109112126B (zh) | 2010-06-23 | 2024-06-14 | 库尔纳公司 | 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病 |
| JP5998131B2 (ja) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー，インコーポレイテッド | Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療 |
| KR101865433B1 (ko) | 2010-10-22 | 2018-07-13 | 큐알엔에이, 인크. | 알파-l 이두로니다아제 (idua)에 대한 자연 안티센스 전사체의 저해에 의한 idua 관련된 질환의 치료 |
| US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
| WO2012071238A2 (en) | 2010-11-23 | 2012-05-31 | Opko Curna Llc | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
| KR102043422B1 (ko) | 2011-06-09 | 2019-11-11 | 큐알엔에이, 인크. | 프라탁신 (fxn)에 대한 자연 안티센스 전사체의 저해에 의한 프라탁신 (fxn) 관련된 질환의 치료 |
| MX365525B (es) | 2011-09-06 | 2019-06-06 | Curna Inc | Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia. |
| HK1210211A1 (en) | 2012-03-15 | 2016-04-15 | 科纳公司 | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| CN102628060A (zh) * | 2012-03-22 | 2012-08-08 | 北京济福霖生物技术有限公司 | 一种低脂奶的生产方法 |
| WO2014069651A1 (ja) * | 2012-11-05 | 2014-05-08 | 塩野義製薬株式会社 | Ｅｌ活性が関連する疾患の治療または予防効果を有する医薬の薬効評価方法及びｅｌ活性阻害物質のスクリーニング方法 |
| BR112015022009A2 (pt) | 2013-03-14 | 2017-08-29 | Shionogi & Co | Anticorpo monoclonal, inibindo a atividade enzimática de lipase endotelial vascular |
| TWI688575B (zh) | 2014-09-11 | 2020-03-21 | 日商塩野義製藥股份有限公司 | 阻礙血管內皮脂酶之酵素活性的人類化單株抗體 |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| JP7851625B2 (ja) * | 2021-07-26 | 2026-04-27 | ピューロテックバイオ株式会社 | 宿主因子ｌｉｐｇをターゲットとした抗ｂ型肝炎ウイルス剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994013791A1 (en) * | 1992-12-04 | 1994-06-23 | Innovir Laboratories, Inc. | Regulatable nucleic acid therapeutic and methods of use thereof |
| US6395530B1 (en) * | 1996-12-06 | 2002-05-28 | Aventis Pharmaceuticals Inc. | LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies |
| WO1999032611A1 (en) * | 1997-12-19 | 1999-07-01 | Progenitor, Inc. | A lipase expressed in endothelial cells and methods for its use |
-
2000
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/ko not_active Ceased
- 2000-03-24 IL IL14552600A patent/IL145526A0/xx unknown
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/es active IP Right Grant
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/ko not_active Expired - Fee Related
- 2000-03-24 EP EP00918362A patent/EP1171078A4/en not_active Ceased
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/ja active Pending
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/en not_active Ceased
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/xx not_active IP Right Cessation
- 2000-03-24 CA CA2363486A patent/CA2363486C/en not_active Expired - Fee Related
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/pt not_active Application Discontinuation
- 2000-03-24 HK HK02104818.0A patent/HK1043309A1/zh unknown
-
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/xx unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/no not_active IP Right Cessation
-
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002540127A5 (https=) | ||
| CA2363486A1 (en) | Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol | |
| Mackness et al. | Paraoxonase activity in two healthy populations with differing rates of coronary heart disease | |
| Bauer et al. | Risk for fracture in women with low serum levels of thyroid-stimulating hormone | |
| Satoh et al. | Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer | |
| US10132809B2 (en) | Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis | |
| Argraves et al. | The atherogenic lipoprotein Lp (a) is internalized and degraded in a process mediated by the VLDL receptor. | |
| Matsuzaki et al. | HOXA-10 expression in the mid-secretory endometrium of infertile patients with either endometriosis, uterine fibromas or unexplained infertility | |
| Trovato et al. | Ad36 adipogenic adenovirus in human non‐alcoholic fatty liver disease | |
| Rasouli et al. | The ratio of apoB/apoAI, apoB and lipoprotein (a) are the best predictors of stable coronary artery disease. | |
| Trujillo et al. | Renal protection by a soy diet in obese Zucker rats is associated with restoration of nitric oxide generation | |
| Ojala et al. | Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non‐familial hypercholesterolaemia | |
| CN100410388C (zh) | 一种鉴定增加骨矿物质密度的化合物的方法 | |
| Zhao et al. | Anti-monocyte chemoattractant protein 1 gene therapy attenuates experimental chronic pancreatitis induced by dibutyltin dichloride in rats | |
| Mera et al. | Clinicopathologic study on prognostic markers in IgA nephropathy | |
| Saha et al. | DNA polymorphisms of the apolipoprotein B gene in Chinese coronary artery disease patients | |
| Kretowski et al. | Polymorphisms of the renin-angiotensin system genes predict progression of subclinical coronary atherosclerosis | |
| De Andrade et al. | Protein nitration, metabolites of reactive nitrogen species, and inflammation in lung allografts | |
| Srinivasan et al. | Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community: The Bogalusa Heart Study | |
| Saitoh et al. | Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands | |
| JP2005537027A5 (https=) | ||
| Marcovina et al. | Lipoprotein (a) and coronary heart disease risk | |
| CN112424609A (zh) | 卒中的血液生物标志物 | |
| JP2003524017A5 (https=) | ||
| Andric et al. | Human cytomegalovirus is present in odontogenic cysts |